GlassScriptPhysician profile
Elizabeth K Odonnell
NPI 1235396730
$128,045.14
in general payments reported to CMS, 2019-2025
14 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $18K · 2021: $8,457 · 2022: $18K · 2023: $44K · 2024: $5,653 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $23K · Travel and Lodging: $14K · Food and Beverage: $1,474 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,085.50 |
| Consulting Fee | $23,359.00 |
| Travel and Lodging | $13,731.34 |
| Food and Beverage | $1,474.02 |
| Education | $316.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $54,139.00 | 2019-2025 | |
| Celgene Corporation | $31,263.52 | 2019-2023 | Abecma |
| E.R. Squibb & Sons, L.L.C. | $17,183.09 | 2022-2024 | Revlimid, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $8,200.00 | 2020-2021 | |
| Pfizer INC. | $4,935.07 | 2021-2025 | |
| Legend Biotech USA INC. | $3,740.00 | 2023 | Carvykti |
| Janssen Scientific Affairs, LLC | $2,502.50 | 2022 | |
| Karyopharm Therapeutics INC. | $2,412.37 | 2020-2023 | Xpovio |
| Janssen Global Services, LLC | $1,860.00 | 2022 | |
| Adaptive Biotechnologies Corporation | $1,353.02 | 2019-2021 | |
| Janssen Biotech, INC. | $456.57 | 2019-2023 | Darzalex, Tecvayli, Carvykti |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Odonnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.